Sullivan Christopher Ryan (CIK 1810417) reported 29 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-18). Recent activity: Buy AVTX (12,394 shares), Sell AVTX (12,394 shares), Buy AVTX (10,185 shares), Sell AVTX (10,185 shares), Buy AVTX (37,945 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 12,394 | $122,453 |
| 2026-09-18 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 12,394 | $202,437 |
| 2026-09-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 10,185 | $81,887 |
| 2026-09-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 10,185 | $179,457 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 37,945 | $374,897 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 2,876 | $28,415 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 37,945 | $753,333 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 3,749 | $74,762 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 31,031 | $306,586 |
| 2026-08-19 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 31,031 | $622,324 |
| 2026-06-12 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 138 | $1,808 |
| 2026-05-26 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 39,900 | $0 |
| 2026-05-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 18,606 | $448,777 |
| 2026-05-11 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 18,606 | $183,827 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Buy | 47,000 | $377,880 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 13,834 | $256,621 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 12,347 | $238,050 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 2,700 | $56,052 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 9,219 | $197,010 |
| 2026-05-07 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,900 | $200,873 |
| 2026-05-01 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,458 | $110,715 |
| 2026-05-01 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 8,457 | $111,886 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 6,200 | $105,524 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 500 | $7,930 |
| 2026-04-03 | Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | Sell | 7,479 | $125,872 |
来源：SEC Form 4 申报文件 · 截至 2026-09-18